Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

Human epidermal growth factor receptor (HER2) negative metastatic breast cancer (BC) accounts for 73% of BC. The molecular analysis of this disease is essential for potential options for targeted therapy. Several promising clinical strategies are being evaluated which includes endocrine therapy, mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Nan, Shi, Yawei, Yu, Liang, Ye, Runyi, Shan, Zhen, Zhang, Zhanqiang, Zhang, Yunjian, Lin, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535782/
https://www.ncbi.nlm.nih.gov/pubmed/31182917
http://dx.doi.org/10.7150/ijbs.30721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535782/
https://www.ncbi.nlm.nih.gov/pubmed/31182917
http://dx.doi.org/10.7150/ijbs.30721

Ejemplares similares